Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy - Full Text View

Sponsored by:	Amgen
Information provided by:	Amgen
ClinicalTrials.gov Identifier:	NCT00035620

Purpose

Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced. Neutrophils are a type of white blood cells that fight infection and are produced in the bone marrow. If the neutrophil count becomes too low due to chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is serious because it can affect the body's ability to protect against many types of infections. Pegfilgrastim is an investigational drug being evaluated for its potential ability to increase the number of neutrophils. The purpose of this study is to determine the safety and effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in pediatric patients up through the age of 21 with sarcoma.

Condition	Intervention	Phase
Sarcoma Neutropenia	Drug: pegfilgrastim Drug: filgrastim	Phase II

MedlinePlus related topics: Cancer Soft Tissue Sarcoma

Drug Information available for: Filgrastim Pegfilgrastim

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients

Further study details as provided by Amgen:

Primary Outcome Measures:

Duration of severe neutropenia in chemotherapy in cycles 1 and 3 [ Time Frame: cycles 1 and 3 ] [ Designated as safety issue: No ]
Time to ANC recovery to greater than or equal to 0.5 x 10^9/L in cycles 1 and 3 [ Time Frame: cycles 1 and 3 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Pharmacokinetic profile in chemotherapy cycles 1 and 3 [ Time Frame: cycles 1 and 3 ] [ Designated as safety issue: No ]
Incidence of adverse events across all cycles of chemotherapy [ Time Frame: all cycles ] [ Designated as safety issue: Yes ]
Overall rates of febrile neutropenia [ Time Frame: all cycles ] [ Designated as safety issue: No ]

Enrollment:	44
Study Start Date:	April 2000
Study Completion Date:	April 2007
Primary Completion Date:	January 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Filgrastim: Active Comparator Filgrastim	Drug: filgrastim filgrastim
Pegfilgrastim: Experimental Pegfilgrastim	Drug: pegfilgrastim pegfilgrastim

Eligibility

Ages Eligible for Study:	up to 21 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Sarcoma * No previous chemotherapy or radiotherapy * Patients who will be receiving chemotherapy consisting of Vincristine, Doxorubicin, Cyclophosphamide, Etoposide, Ifosfamide, and Mesna

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035620

Sponsors and Collaborators

Amgen

Investigators

Study Director:

MD

Amgen

More Information

AmgenTrials clinical trials website This link exits the ClinicalTrials.gov site

Responsible Party:	Amgen Inc. ( Global Development Leader )
Study ID Numbers:	990130
Study First Received:	May 3, 2002
Last Updated:	March 27, 2008
ClinicalTrials.gov Identifier:	NCT00035620
Health Authority:	United States: Food and Drug Administration

Keywords provided by Amgen:

Bone cancer
Sarcoma
Neutropenia
Chemotherapy

Study placed in the following topic categories:

Neoplasms, Connective and Soft Tissue
Neutropenia
Bone Neoplasms
Hematologic Diseases
Malignant mesenchymal tumor
Bone neoplasms

Agranulocytosis
Sarcoma
Leukocyte Disorders
Leukopenia
Granulocytopenia
Soft tissue sarcomas

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on January 16, 2009